Last updated 2026-07-26
- Raised $78M Series D led by Arboretum Ventures, Sep 2024
- Raised $30M Series C led by Bluestem Capital, Aug 2020
- Raised $13M Series B led by Sequoia Capital, May 2018
Total raised
$121.0M
Last: Undisclosed Round 2024-10
Stage
Series D
Founded
2015
Headcount
87
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences
About
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company focused on delivering solutions to reshape vision possibilities. The company has developed Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%, a novel corrective eye drop for the treatment of presbyopia, or age-related blurry near vision, in adults. Presbyopia is the gradual loss of the eye's ability to focus on near objects as a result of the natural aging process, affecting almost two billion people globally. Orasis aims to provide an alternative to reading glasses. Orasis has offices in the U.S. and Israel.
Funding history · 5 rounds · $121.0M total
2024-09
D Round
$78.0M
★ Arboretum VenturesSequoia CapitalBluestem CapitalVisionary VenturesSBI JI Innovation FundMaverick Ventures IsraeICatalio Capital ManagementJohnson & Johnson Innovation
2022-04
C Round Extension
Undisclosed
★ David Almagor
2020-08
C Round
$30.0M
★ Bluestem CapitalSequoia CapitalVisionary VenturesSBI JI Innovation FundMaverick Ventures IsraeILifeSci Venture Partners
2018-05
B Round
$13.0M
★ Sequoia Capital★ Visionary Ventures★ RIO Ventures Holdings★ SBI JI Innovation Fund★ Maverick Ventures IsraeI★ LifeSci Venture Partners
2015-12
A Round
Undisclosed
★ Sequoia Capital
Headcount over time
From 5 (2018-12) to 84 (2026-03) · +79 (+1580%) · 16 points · source: Finder history + radar grounding
Q&A
- What is Orasis Pharmaceuticals' primary product?
- Orasis Pharmaceuticals has developed Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%, a corrective eye drop for the treatment of presbyopia, or age-related blurry near vision, in adults.
- When was Orasis Pharmaceuticals founded?
- Orasis Pharmaceuticals was founded in September 2015.
- What was the most recent funding round for Orasis Pharmaceuticals?
- In October 2024, Orasis Pharmaceuticals completed a D Round funding of $68,000,000. Lead investors included Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc.
- What is the total amount of funding Orasis Pharmaceuticals has raised to date?
- Orasis Pharmaceuticals has raised a total of $131,000,000 in funding.
- Has Orasis Pharmaceuticals' primary product received FDA approval?
- Yes, in October 2023, Orasis Pharmaceuticals announced FDA approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia.
- In what countries does Orasis Pharmaceuticals have offices?
- Orasis Pharmaceuticals has offices in Israel and the United States.
- What is the employee count for Orasis Pharmaceuticals?
- Orasis Pharmaceuticals has 51-200 employees.
- Did Orasis Pharmaceuticals secure a licensing agreement for Qlosi in Korea?
- Yes, in October 2024, Orasis announced a licensing agreement with Optus Pharmaceuticals for the commercialization of Qlosi eye drops in Korea.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsophthalmologydrug-discoveryeye-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | orasis-pharma.com/ |
|---|---|
| linkedin.com/company/10476373 | |
| Wikidata | wikidata.org/wiki/Q30269240 |
Identifiers & details
| Legal name | Orasis Pharmaceuticals Ltd. |
|---|---|
| Founded | 2015-9 |
| Employees (exact) | 87 |
| Offices | Ponte Vedra Beach |
| Wikidata QID | Q30269240 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | orasis-pharma.com |
|---|
Wikidata
| QID | Q30269240 |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515317493 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-09-24 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 5 — shares_capital (3), other (2) |
| Registered address | משכית 2 הרצליה |
Recent registry events
| Date | Event |
|---|---|
| 2025-08-31 | העברת מניות |
| 2026-07-21 | שינוי בהרכב הון - מניות-הפחתת הון מוקצה |
| 2025-08-18 | הקצאת מניות |
| 2025-12-16 | הוספה/עדכון/הסרה של צו עיקול |
| 2026-07-06 | עדכון כתובת ו/או מען דיגיטלי |